Therapeutic Area

Antiarrhythmic

Therapeutic area intelligence for Antiarrhythmic with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 1

Companies

OMSAV PHARMA →

Assets

FDA →

Recent signals(2)

RegulatoryJuly 5, 2026

FDA Grants Approval for Flecainide Acetate ANDA218093 by OMSAV PHARMA

The FDA has granted approval for the ANDA218093 application for Flecainide Acetate submitted by OMSAV PHARMA.

RegulatoryJune 30, 2026

FDA Grants AP Status for Sotalol Hydrochloride ANDA207429

The FDA has granted approval status (AP) for the ANDA207429 application for Sotalol Hydrochloride submitted by Regcon Holdings.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.